Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice

J Exp Med. 1996 Oct 1;184(4):1561-6. doi: 10.1084/jem.184.4.1561.

Abstract

Castleman's disease is a lymphoproliferative disorder thought to be related to deregulated production of IL-6. We have previously shown that mice lacking the trans-acting factor C/EBP beta, a transcriptional regulator of IL-6 and a mediator of IL-6 intracellular signaling, develop a pathology nearly identical to multicentric Castleman's disease, together with increasingly high levels of circulating IL-6. We describe here how the simultaneous inactivation of both IL-6 and C/EBP beta genes prevents the development of pathological traits of Castleman's disease observed in C/EBP beta-deficient mice. Histological and phenotypic analysis of lymph nodes and spleen of double mutant mice did not show either the lymphoadenopathy and splenomegaly or the abnormal expansion of myeloid, B and plasma cell compartments observed in C/EBP beta-/- mice, while B cell development, although delayed, was normal. Our data demonstrate that IL-6 is essential for the development of multicentric Castleman's disease in C/EBP beta-/- mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • B-Lymphocytes / pathology
  • CCAAT-Enhancer-Binding Proteins
  • Castleman Disease / genetics*
  • Castleman Disease / pathology
  • Castleman Disease / prevention & control
  • DNA-Binding Proteins / genetics*
  • DNA-Binding Proteins / metabolism
  • Flow Cytometry
  • Interleukin-6 / genetics*
  • Lymph Nodes / pathology
  • Mice
  • Mice, Mutant Strains
  • Nuclear Proteins / genetics*
  • Nuclear Proteins / metabolism
  • Phenotype
  • Plasma Cells / pathology
  • Spleen / pathology
  • Thymus Gland / pathology

Substances

  • CCAAT-Enhancer-Binding Proteins
  • DNA-Binding Proteins
  • Interleukin-6
  • Nuclear Proteins